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Abstract 
 
Prostate Cancer (PCa) is a highly heritable disease, and rapid evolution of 
sequencing technologies has enabled marked progression of our understanding of 
its genetic inheritance . A complex polygenic model that involves common low 
penetrance susceptibility alleles causing individually small, but cumulatively 
significant risk, and rarer genetic variants, causing greater risk, represent the current 
most accepted model. Through Genome Wide Association studies, more than 100 
SNPs associated with PCa risk have been identified. Consistent reports have 
identified germline mutations in the genes BRCA1, BRCA2, MMR, HOXB13, CHEK2, 
NBS1, as conferring moderate risks, with some leading to a more aggressive 
disease behaviour. Considering this knowledge, several research strategies have 
been developed to determine if targeted prostate screening using genetic information 
can overcome the limitations of population-based PSA screening. Germline DNA-
repair mutations are more frequent in men with metastatic disease than previously 
thought, and these patients have a more favourable response to therapy with 
poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors.  Genomic 
information is a practical tool that has the potential to enable the concept of precision 
medicine to become a reality in all steps of PrCa patient care. 
 
 
1. Introduction 
Family history, ethnicity and age are the only risk factors for prostate cancer 
(PCa) that have been consistently established. Some families display significant 
aggregation of PCa cases A man with a first degree relative affected by the disease has at 
least twice the chance of developing this condition compared with the general 
population [1]The risk increases even further if more than one relative is affected and 
also if the related case presented with early onset PCa [2]. For first degree relatives of 
cases diagnosed before the age of 65, the estimated relative risk (RR) is 3.4 (95% CI 
[Confidence Interval] 2.7-4.2) [3]. When 2 first degree relatives are affected, the pooled 
RR is 4.39 (CI 2.6-7.4) [4].  Studies analysing Nordic twin registries have demonstrated 
at least a 50% higher risk in monozygotic than dizygotic twins. This, associated with the 
higher incidence in African American men suggests that genetic, rather than shared 
lifestyle factors, are responsible for much of the familial aggregation [5-7]. A large 
prospective cohort study estimated that genetic variation can explain 58% of the 
liability to develop PCa [8] 
2. Genetic Models 
Genetic predisposition variants associated with PCa consist of a mixture of 
models, ranging from rare higher penetrance genes to common variants associated with 
a slightly increased risk per variant (although the cumulative risks can be substantial as 
there are many such variants whose risks are multiplicative). Segregation analyses of 
PCa family pedigrees have suggested a major genetic component as the causative factor. 
The hypothesis of a dominant pattern of inheritance was supported in some specific 
subsets of families [9, 10]. However, the genetic model on further studies has been 
shown to be complex and includes a recessive and X-linked form of inheritance in some 
modelling studies [11, 12]. The suggestion of a potential high risk genetic component 
has spurred the use of linkage studies in pedigrees with multiple affected individuals in 
an effort to identify these genes. 
 
a. Evidence from Linkage Studies 
Linkage is the co-segregation of genetic markers with a disease, and can be used 
to indicate the likely location of disease predisposition genes. The measure of the 
likelihood of linkage is defined as the “logarithm of odds” (LOD) [13].  Different linkage 
studies described associations with several candidate locus, including 1q42, 1p36, 
8p22-23, 17q11, 20p13, Xq27-28, [14-20]. However, these findings were not 
consistently reproduced, casting doubt on their true association with PrCa risk. In 2005, 
the International Consortium for Prostate Cancer Genetics (ICPCG) reported the largest 
study to date, combining data from 1,233 families from 10 international groups [21], 
identifying only one locus with a LOD >3 located on 22q, and was only observed in 
families with high early-onset PCa aggregation. Recently, a successful approach involved 
the sequencing of a linkage region at 17q, which found mutations in the gene HOXB13, 
associated mainly with young onset and familial PCa [22].  Despite these isolated 
successful results, linkage analysis failed to provide definitive findings, suggesting a 
much more complex model of PCa susceptibility. 
 It is clear today that the inheritance model of a highly penetrant gene associated 
with a high risk is clearly not enough to account for all genetic burden of the disease, 
with multiple genes (polygenic inheritance) likely to be involved. A model based on 
several different common and low penetrance mutations is more adequate to account 
for the majority of PCa cases. Conversely, a small proportion of cases, especially those 
with early onset and strong familial aggregation, possibly harbour rarer, higher risk 
mutations.  This came to light as the correct model for PCa predisposition (Fig. 1).  
 
  
Figure1. Genetic predisposition to prostate cancer. 
Modified From: Mikropoulos et al. [23] 
 
a. Genome wide association studies and clinical implications  
The pitfalls of the linkage analysis to search the genome, especially to identify 
low-penetrance and high frequency risk determinants, exposed the need for a different 
approach. In contrast with hypothesis-based previous studies, in Genome Wide 
Association Studies (GWAS) an agnostic approach is employed, comparing the 
frequency of Single Nucleotide Polymorphism (SNPs) between cases and controls 
throughout the genome. 
A SNP is one the most common type of human genetic variation. It is a difference 
in a single nucleotide base pair in the DNA sequence between members of the same 
species. The frequency of this allelic variation is usually at least 1% to be considered a 
polymorphic SNP (Pearson and Manolio 2008)[24]. Tag-SNPs’ are SNPs in genomic 
regions of linkage disequilibrium with a causal variant. Tag-SNPs are useful as they can 
infer associations with other SNPs, but they are limited in that they might just be 
markers of the pathogenic SNPs [25, 26]. Frequently 300,000 to over two million SNPs 
can be genotyped in several thousands of samples on high- density microarrays. It has 
been an excellent tool to identify low penetrance susceptibility loci for many complex 
diseases. As so many data points are analysed at once, the level of genome-wide 
significance that needs to be achieved is P <of 5x10-8  
8q24 was the first region identified [27] and is the region that has the highest 
number of independently associated variants, with different groups reporting 16 
independent SNPs in genome wide searches, in diverse ethnic groups of men  [28-32]. 
The contribution to the total risk seems to be larger in men of African ancestry [32, 33], 
and a recent report identified 2 risk variants only found in men of African ancestry and 
a novel signal, rs111906923, in this region [34]. These SNPs are located near or within 
many PCa associated long non-coding RNAs (lncRNAs). This finding reinforces the 
hypothesis that lncRNAs might have a role in ancestry-specific PCa predisposition [35, 
36]. Additionally, the 8q24 region is located in the vicinity of MYC, a known oncogene. 
Using a chromosome conformational capture essay (3C), Ahmadyeh et al [37] presented 
evidence that support the role  of 3 independent 8q24 subregion (region1: 128.54-
128.62, region 2 128.14-128.28, region 3 128.47-128.54) as regulatory enhancers, with 
interaction with  C-MYC. 
Another SNP (rs11568818) with potential prognostic value is situated at 11q22 
within a region containing the gene MMP7. MMP7 encodes for a matrix metal-
loproteinase, which is pivotal for tumour metastasis, and overexpression of MMP7 is a 
potential biomarker for PCa aggressiveness and risk of metastatic disease [38]. Also 
high serum concentration of MMP-7 [38] and polymorphisms in this gene [39] are 
correlated with poorer outcome after radical treatment. 
rs7141529 is within the locus of RAD51B. The RAD51 protein family is involved 
in DNA repair mechanisms [40], and disruption of the DNA repair pathway is now 
thought to be important in the development of many cancers [41]. 
SNP rs2735839 was identified between the KLK2 and KLK3 genes on 
chromosome 19 in which there is a kallikrein gene cluster [46]. Kallikreins are serine 
proteases and the most recognized member of this group is the prostate-specific 
antigen (PSA). Fine mapping of the region at 19q13 led to the identification of a coding 
SNP in KLK3 that showed a stronger association with PrCa risk than the original SNP 
identified from GWAS, and this novel SNP potentially changes some characteristics of 
the PSA molecule  [42]. 
Different groups reported the same hit on chromosome 10, rs10993994, close to 
the transcription start site of the microseminoprotein beta (MSMB) gene [30, 43]. The 
product of this gene is a 10.7 kD non-glycosylated cysteine-rich protein that is 
synthesized by epithelial cells in the prostate and secreted into seminal fluid [44]. It can 
be measured in the plasma and urine, and it is one of the three most common proteins 
secreted by the prostate gland [45]. Reduced levels are seen in early disease, in tumour 
tissue, as demonstrated by immunohistochemistry, and also in the urine [46]. Also, a 
comprehensive recent report assessed tissue and serum expression using 
immunohistochemistry, RT-qPCR and genotyping of rs10993994 in patients with 
benign hyperplasia, early and advanced PCa, demonstrated that decreased expression of 
MSMB parallels cancer progression, and adjusted MSMB serum levels correlates with 
PCa risk [47].  These characteristics make MSMB a potential screening target and 
prognostic determinant, probably to be used in addition to PSA rather than replacing it 
[48]. 
Although each susceptibility allele is known to confer only a small increased risk 
individually their risks act multiplicatively [49, 50]. From the current 41 GWAS, more 
than 100 SNPs are independently associated with PCa risk and explain approximately 
33% of the familial risk of the disease (Table 1). Fine-mapping of these GWAS region 
also proved to be  very important as it can not only discover multiple independent hits 
in a region but also often can replace the original tag SNPs with a better,  more 
significantly associated variant, hence risk prediction will also be more precise using 
these newly discovered variants [51].  Men in the top 1% of the genetic risk profile of a 
population typed for these SNPs would have a 5.7-fold increased relative risk of PCa 
development in comparison with the average of the population [52]. In the near future, 
the novel findings from the Oncoarray Consortium will add new and relevant 
information about the association of common genetic variants and PCa. 
This risk stratification approach can lead to a new way to select men for early 
detection programmes, potentially overcoming many of the limitations of PSA-based 
screening. Using 26 SNPs and family history,  MacInnis et al. [53] developed an 
algorithm that has the potential to predict individual PCa development risk. Newly 
discovered SNPs can be added to the equation, as long as they contribute 
multiplicatively to the risk, allowing updated SNP-based risk stratification as new 
discoveries are confirmed. Once validated in prospective series, this can become a 
useful tool in screening decisions in clinical practice. 
Recently, the results of the Stockholm 3 (STHLM3) study were published. This 
prospective screening cohort involved 58,818 participants, aged 50–69 years. A PSA-
only based detection protocol was compared with the STHLM3 model, which employed 
plasma protein biomarkers (PSA, free PSA, intact PSA, hK2, MSMB, MIC1), genetic 
polymorphisms (232 SNPs), and clinical variables (age, family history, previous prostate 
biopsy, prostate examination). The model outperformed PSA alone for detection of 
cancers with a Gleason score ≥7 (P<0.0001), with an area under the curve (AUC) of 0.74 
(95% CI 0.72–0.75), compared with an AUC of 0.56 (95% CI 0.55–0.60) for PSA alone 
[54]. 
 A study investigated targeted screening in men with family history. The 
PROFILE feasibility study involved 115 men with a PrCa family history and who were of 
Caucasian origin. One hundred patients underwent a TRUS prostate biopsy at study 
enrollment, and the results were correlated with clinical variables and a polygenic risk 
score (PRS), based on 71 SNPS. Twenty-five PrCa cases were detected, with 12 (48%) 
classified as intermediate or high-risk disease, requiring active treatment. This number 
is almost twice as expected based on the Prostate Cancer Prevention Trial data [55]. Age 
at study entry and PSA were predictors of PrCa diagnosis. No significant association was 
found between the PRS and biopsy outcome. However, this initial pilot was not powered 
to detect this difference [56]. A more extensive main PROFILE study of 700 men is in 
progress and has incorporated multiparametric MRI into the screening algorithm. The 
conclusion of the main study will provide invaluable evidence as to whether a SNP 
profile will be helpful in the screening of higher risk men. 
The routine use of risk SNPs profiling in public health would require further 
evidence. In the next few years large studies in this area will be crucial to determine the 
role of this tool in population-based screening programs [57]. 
Copy number variations (CNV) are a distinct class of germline polymorphisms 
and recently have been associated with cancer predisposition [58]. In an analysis of 
1900 Caucasian men, Demichelis et al, reported 2 low-frequency CNV strongly 
associated with PCa [59]. The firs locus, mapping to 15q21.3, overlaps a noncoding 
element that hold multiple activator protein 1 (AP-1) transcription factor binding sites. 
The second on 12q21.31, maps directly to α-1,3-mannosyl-glycoprotein 4-β-N 
acetylglucosaminyltransferase C (MGAT4C) gene. This glicosyltransferase is 
involved in regulationg cell-cell adhesion in epithelia. These findings were replicated 
in an independent cohort, and illustrate that germline CNV may be involved in 
mechanisms of carcinogenesis regulation and progression.    
2. Rare Variants  
 The evidence from GWAS allowed clarification of a significant proportion of the 
inherited PCa risk. This technique is powered to detect common variants, with 
frequency >5%, not detecting less common risk alleles. Studies employing direct testing 
in a large number of cases and controls using next-generation sequencing have 
consistently reported a few rare genes, with moderate to highly penetrance that confer 
moderate to high individual risk. 
 
a. BRCA1/2 and implications for targeted screening 
The most reproducible results came from analysis of germline mutations in 
breast cancer predisposition cancer genes 1 and 2 (BRCA1 and BRCA2). BRCA1 and 
BRCA2 are tumour suppressor genes, coding large proteins, inherited in a dominant 
fashion with incomplete penetrance [60]. BRCA1 is a protagonist in cellular control 
mechanisms, acting in DNA damage response and repair, transcriptional regulation and 
chromatin modelling. BRCA2 is likely to be related to DNA recombination and 
restoration processes, via interactions with RAD51 and PALB2 [61]. BRCA1/2 
impairment results in a deficiency in repairing DNA double-stand breaks by the 
conservative approach of homologous recombination (HR) [62]. Affected cells start to 
employ potentially mutagenic pathways to repair these lesions [63]. 
Tumorigenesis in individuals with germline mutations in BRCA genes usually 
demands somatic inactivation of the remaining wild type allele in a tumour suppressor 
model, although there are rarer reports of haplo-insufficiency from loss of the mutant 
copy [64]. The genomic instability generated is believed to be the mechanism for the 
cancer predisposition observed 
Clear evidence has shown that mutations of the tumour suppressor BRCA2 gene 
predispose men to PCa. This predisposition was reported by the Breast Cancer Linkage 
Consortium (BCLC), which analysed men in families with a history of breast and ovarian 
cancers (also BRCA-driven malignancies). Their data estimated that men with germline 
BRCA2 mutations have an approximately five-fold higher relative risk of PCa than men 
without BRCA2 mutations. This risk increases to over seven-fold in families with men 
with early onset PCa (<65 years) [65, 66]. Subsequent studies pointed to an even higher 
risk with an estimated lifetime absolute PCa risk around 15% at the age 65, 
corresponding to an increased relative risk of approximately 8.6-fold [67]. 
By contrast, the relative risk of prostate cancer in young BRCA1 mutation 
carriers is controversial. These patients have been shown to have a smaller, though 
consistent, increased relative risk, with an estimate of 1.8- fold to 4.5-fold, representing 
a cumulative risk at 65 years of up to 8.6% [68, 69]. 
Despite representing a small fraction of PCa cases (0.45% and 1.2% for BRCA1 
and 2, respectively) [67, 68], BRCA mutation carriers have repeatedly been shown to 
have aggressive disease [70-73]. In the largest analysis of clinical characteristics of PCa 
patients who are BRCA carriers to date, Castro et al. [74] reported a larger proportion of 
high grade disease, Gleason score >8, nodal involvement and metastatic presentation 
amongst carriers than controls. Moreover, cancer specific survival and metastasis free 
survival were both significantly higher in noncarriers.  It is possible that this occurs 
because there is a higher incidence of copy number variation in PCa tumour and normal 
prostatic tissue in germline BRCA  mutation carriers [75].The sum of all evidence points 
toward the rationale for a more aggressive early detection strategy and management of 
PCa in BRCA mutated patients. 
Currently, a large multicentre international study is investigating the use of 
targeted PSA screening in BRCA mutation carriers. The IMPACT study (Identification of 
Man with a genetic predisposition to ProstAte Cancer: Targeted screening in men with 
BRCA1/2 mutations) [76, 77] has recruited to date 2481 mutation carriers and controls. 
The results of the first screening round, published in 2014, showed a predictive positive 
value (PPV) of biopsy using a PSA threshold of 3 of 37.5% in BRCA1 carriers and 23.3% 
in controls;   48% in BRCA2 carriers and 33.3% in BRCA2 controls. Furthermore, the PPV 
for detection of clinically significant disease (intermediate and high grade) was higher 
in the BRCA2 carrier group when compared to controls, 2.38% and 0.71%, respectively 
(Pearson p=0.04) [78]. The final report will present the results of 5 screening rounds. 
 
b.  Lynch Syndrome 
A patient group in which a higher PCa risk has been reported is men with Lynch 
syndrome. Lynch syndrome is a multicancer syndrome caused by germline mutations in 
the MMR genes; MLH1, MSH2, MSH6, and PMS2. Colorectal cancer and endometrial 
cancer are a predominant feature, with a 70% and 50% lifetime risk, respectively [79]. 
There is increasing evidence that PCa risk is also increased in Lynch syndrome. From 
the Manchester Regional Lynch Syndrome Database, enrolling 821 men, Barrow et al 
[80] described a 10.41-fold increase in PCa risk (95% CI 2.8–26.65). In one of the largest 
cohorts to date, Engel et al. [81] analysed 2,118 MMR gene mutation carriers, and found 
a cumulative incidence of 9.1% with a standard incidence ratio of 2.5 (95% CI 1.4–4.0). 
Both of these studies agreed that there is a preponderance of MSH2 mutations among 
PCa patients with Lynch syndrome. In a recent meta-analysis, Ryan et al [82] estimates 
a 2.28-fold increased PCa risk (95% CI, 1.37–3. 29) for all men from mutation-carrying 
families. 
c. HOXB13 
 Another gene currently of interest is the HOXB13,   Homeodomain-containing 
proteins (HOX) are a large class of sequence-specific transcription factors. Humans have 
39 HOX genes, arranged in 4 chromosomal clusters, named HOXA, HOXB, HOXC, and 
HOXD [83]. The core function is to specify the identity of body segments along the AP 
axis during embryonic development, and HOXB13 plays a crucial role in the prostate 
development [84]. Interaction of HOXB13 and Androgen receptor has been 
demonstrated in normal and PrCa cells [85], with functions of different androgen 
targets. Therefore, HOXB13 seems to be an important regulator of cellular response to 
androgens [84, 86]. 
Ewing et al. [22] reported the association of a rare germline mutation (G84E) in 
the HOXB13 gene with an increased risk of hereditary PCa. This mutation (G84E) was 
genotyped in 2443 PCa families recruited by the International Consortium for Prostate 
Cancer Genetics and was found in 4.6% of families,  all of  European descent. It was 
more common in Nordic countries and less common in North America and Australia. 
And within HOXB13 carrier families the G84E mutation was more common in men with 
a diagnosis of PCa [70]. A meta-analysis of 24 trials with 97,844 participants by Shang et 
al. identified that the frequency of the G84E mutation was higher among cases with 
younger age at onset with an OR (odds ratio)  of 10.1 (95% CI: 5.97–17.12) and among 
patients with family history, with an OR of 5.01 [71]. The meta-analysis by Huang et al. 
of 11 studies with 120,617 men measured the relative risk of PCa as 4.51-fold for 
HOXB13 G84E carriers and also highlighted that this variant is associated with early-
onset (OR: 9.73), familial (OR: 7.27) and high-risk (OR: 5.81) PCa [72]. A large case-
control study involving Caucasian British men reported an incidence of 1.5% of the 
variant among PCa cases, associated with a 2.93-fold increased risk [87].  
The clinical utility of this finding remains to be determined. 
 
d. CHEK2 
In response to genotoxic insults causing double strand DNA breaks, CHEK2 is 
activated and propagates the checkpoint signal along diverse pathways, leading to cell 
cycle arrest, activation of DNA repair mechanisms and eventually apoptotic cell death 
[88]. CHEK2 variants have been associated with PCa risk. A recent report from the 
Copenhagen general population study found that CHEK2*1100delC heterozygotes had 
an adjusted hazard ratio for PCa of 1.6. A pooled analysis of 5 studies described an OR of 
1.98 (95%CI 1.23–3.18) in unselected cases and 3.39 (95%CI 1.78–6.47) in familial 
cases. [89]   
e. NBS1 
 The product of the gene Nijmegen Breakage Syndrome NBS1 is a component of 
the BRCA1 DNA-damage response pathway [90].  A candidate gene analysis involving 
1861 individuals reported a higher frequency of the founder mutation 657del5 in 
patients with familial PCa, when compared with patients with sporadic PrCa and 
controls  (OR = 16, P=0.0001).  In a study involving 7706 patients, the same founder 
mutation was more frequent in cases than controls with an OR = 2.5 (P=0.0003). 
Additionally, this variant was associated with a worse prognosis [91].   
 
3. Germline Genetic variants and treatment outcomes 
Evidence is emerging that germline variants can influence diverse treatment 
modalities has been accumulating in recent years, making the use of genetic information 
to guide treatment decisions a realistic perspective. 
 Using the 23 SNPs discovered with the Collaborative Oncological Gene-
Environment Study array (iCOGS)  Kearns et al. described that rs11568818 was 
associated with pathological upgrading in a prospective cohort of surgically treated 
patients. This finding was confirmed in a second cohort of patients on active 
surveillance (AS), in which rs11568818 was associated with pathological upgrading on 
surveillance biopsies [92]. It has been shown that on average 30% of patients on AS will 
move to definitive treatment in the first 5 years, and genetic information that could 
inform a more precise stratification before AS enrolment would be of great value. 
The mechanisms involved in radiation-induced tissue damage are complex, and 
it is likely that genetic variation is one of determinants of individual response. A three-
stage GWAS identified association between a locus comprising TANC1 at 2q24.1 and late 
radiotherapy toxicity, with a combined P value = 4.64x10-11 [93].  An additional GWAS 
enrolling 663 patients treated with radical radiotherapy described more association 
between common variants and treatment toxicity than expected by chance, at a 
significance level of p= 5x10-7 [94]. In a study of 1560 patients from 4 radiotherapy 
cohorts, Ahmed et al demonstrate that 75 SNPs associated with PrCa risk are not 
predictors of radiotherapy toxicity, showing that men with genetic predisposition due 
to common variants can be safely treated with current radiotherapy regimens, and 
illustrating that many of the individual determinants of radiation toxicity are yet to be 
identified [95]. 
Castro et al. investigated the influence of BRCA mutations on PCa treatment 
outcomes in a cohort of 1302 patients, including 67 BRCA mutation carriers. The 
authors reported that carriers when treated with curative intent modalities (either 
radiotherapy or radical prostatectomy) develop metastasis sooner and had shorter 
survival than noncarriers [96]. BRCA mutation carriers with organ confined PCa were 
treated on protocols developed for noncarriers, and this study provided the first 
evidence that this may not be the ideal approach. 
 A recent multicentre study described that deleterious germline DNA-repair 
mutations are more frequent in men with metastases than described in the overall PCa 
population, including patients with localized disease. These mutations were identified 
in 11.8% (82) of 692 patients with documented metastatic disease. BRCA2 (5.3%), ATM 
(1.6%) and CHEK2 (1.9%) were the most frequent (Fig. 2) [97], A previous report in 191 
familial PCa cases showed a frequency of 7.3% of mutations in at least one of 22 crucial 
tumour suppressor genes (BROCA panel) [98].  
 
Figure 2. Distribution of DNA-repair germline mutations among 82 patients with 
metastatic prostate cancer. From Pritchard et al. [97] 
In a phase 2 study of castration-resistant PCa patients, Mateo et al. described that 
patients with somatic or germline mutations in DNA-repair genes had a significantly 
higher response to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 
inhibitors. From 16 patients which such mutations, 88% responded, including 100% of 
patients with BRCA2 loss [99]. Also, BRCA2 biallelic loss appears to be related with 
platinum-based chemotherapy sensitivity [100] . These findings, associated with the 
increased incidence of germline mutations in the metastatic setting, illustrate the 
potential for a genomic-based approach to treatment. The presence of an increased  
frequency of germline mutation in the metastatic setting has been demonstrated mainly 
for breast and prostate, however, there is a clear rationale for its role as a common  
feature of aggressive cancer.  
4. Conclusion 
 Our understanding of PCa genetics is growing at an accelerated pace. The 
potential clinical implications are applicable at every crucial step of the patient care 
pathway:  from selection of patients for screening, guiding treatment decisions at 
diagnosis to targeted systemic therapy in the metastatic setting, thus making genomic 
information as a practical tool to enable the concept of precision medicine to become a 
reality.  
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